Methods for the use of spermidine/spermine N.sup.1 -acetyltransferase as a prognostic indicator and/or a tumor response marker
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 12, 1996
Issued Date -
N/A
app pub date -
Nov 16, 1993
filing date -
Apr 28, 1992
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Disclosed is a method that relates to the measurement of determinants related to the in-vivo induction of spermidine/spermine N.sup.1 -acetyltransferase (SSAT), subsequent to polyamine analog treatment (such as with a bis-ethyl spermine analog) of human malignant solid tumor types responsive to the polyamine analog. The method comprises the measurement of one or more SSAT-specific determinants that include SSAT enzyme activity, SSAT enzyme protein, and SSAT m-RNA transcripts. Alternatively, other determinants related to the SSAT induction may be measured. Such determinants include SSAT co-factor acetylCoenzyme A, and SSAT products N.sup.1 -acetylspermidine and N.sup.1 -acetylspermine. Measurements of these determinants may be useful as prognostic indicia and tumor response markers to evaluate the clinical effectiveness of anticancer agents comprising polyamine analogs.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully